Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

16-02-2017 | Image

Figure 3: Therapeutic induction of cell death through targeting of the mitochondrial apoptosis pathway.

Proteins in the BCL-2 family are classified into pro-survival (orange colour) and pro-apoptotic groups. The pro-apoptotic proteins are further sub-divided into BCL-2 homology 3 (BH3)-only proteins (green colour) and effector proteins (blue colour).

print
PRINT
Image Credits